Literature DB >> 12721394

Reactive metabolites and adverse drug reactions: clinical considerations.

Sandra R Knowles1, Lori E Shapiro, Neil H Shear.   

Abstract

Idiosyncratic reactions can affect many different organ systems, either as -an isolated event (e.g., hepatitis) or as part of a syndrome (e.g., drug hypersensitivity syndrome). Formation of reactive metabolites of drugs in conjunction with a decreased ability for detoxification is believed to be the initiating step in many idiosyncratic reactions. The drug hypersensitivity syndrome, defined by the presence of fever, rash and internal organ involvement, is estimated to occur in approx 1 in 1000 to 1 in 10,000 exposures with drugs such as anticonvulsants sulfonamide antibiotics, allopurinol, and dapsone. Symptoms usually start within 2-8 wk of drug initiation. Serum sicknesslike reaction, most frequently found after 7-14 d of drug exposure, is distinguished by a fever, cutaneous eruption and arthralgias. Medications such as cefaclor, minocycline and bupropion are most frequently implicated in this reaction. In contrast, drug-induced lupus can occur l-2 yr after initiation of medication. Drug-induced lupus is characterized by musculoskeletal complaints and fever and weight loss. Drugs most commonly associated with drug-induced lupus include procainamide, hydralazine, chlorpromazine, isoniazid, and minocycline. Management of patients who develop idiosyncratic reactions includes discontinuation of the implicated drug, initiation of corticosteroids (when appropriate), and symptomatic relief as required. Internal organ involvement, which may initially be asymptomatic, should be monitored. Confirmatory or diagnostic tests are not readily available in most areas, except for research purposes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12721394     DOI: 10.1385/CRIAI:24:3:229

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  54 in total

1.  Antinuclear and antinucleolar antibodies in patients with scleroderma-polymyositis overlap syndrome.

Authors:  M Hietarinta; O Meyer; T Haim; A Elias; M F Kahn
Journal:  Br J Rheumatol       Date:  1996-12

2.  Bioactivation of phenytoin by human cytochrome P450: characterization of the mechanism and targets of covalent adduct formation.

Authors:  A J Munns; J J De Voss; W D Hooper; R G Dickinson; E M Gillam
Journal:  Chem Res Toxicol       Date:  1997-09       Impact factor: 3.739

3.  Sulfamethoxazole is metabolized to the hydroxylamine in humans.

Authors:  A E Cribb; S P Spielberg
Journal:  Clin Pharmacol Ther       Date:  1992-05       Impact factor: 6.875

Review 4.  Metabolic activation in drug allergies.

Authors:  B K Park; D J Naisbitt; S F Gordon; N R Kitteringham; M Pirmohamed
Journal:  Toxicology       Date:  2001-02-02       Impact factor: 4.221

5.  Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity.

Authors:  D J Naisbitt; S J Hough; H J Gill; M Pirmohamed; N R Kitteringham; B K Park
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

6.  Cefaclor serum sickness.

Authors:  L C Grammer
Journal:  JAMA       Date:  1996-04-17       Impact factor: 56.272

7.  A novel lymphocyte toxicity assay to assess drug hypersensitivity syndromes.

Authors:  M G Neuman; I M Malkiewicz; N H Shear
Journal:  Clin Biochem       Date:  2000-10       Impact factor: 3.281

8.  Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis.

Authors:  P Wolkenstein; J Latarjet; J C Roujeau; C Duguet; S Boudeau; L Vaillant; M Maignan; M H Schuhmacher; B Milpied; A Pilorget; H Bocquet; C Brun-Buisson; J Revuz
Journal:  Lancet       Date:  1998-11-14       Impact factor: 79.321

9.  Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.

Authors:  I Viard; P Wehrli; R Bullani; P Schneider; N Holler; D Salomon; T Hunziker; J H Saurat; J Tschopp; L E French
Journal:  Science       Date:  1998-10-16       Impact factor: 47.728

10.  N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes.

Authors:  A E Cribb; S P Spielberg; G P Griffin
Journal:  Drug Metab Dispos       Date:  1995-03       Impact factor: 3.922

View more
  7 in total

1.  Case Report: A Case of Type 1 Leprosy Reaction and Dapsone Hypersensitivity Syndrome Complicating the Clinical Course of Multibacillary Leprosy.

Authors:  Jeffrey Craig; Cara MacRae; Rochelle G Melvin; Andrea K Boggild
Journal:  Am J Trop Med Hyg       Date:  2019-05       Impact factor: 2.345

Review 2.  Patch testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review.

Authors:  Abdelbaset A Elzagallaai; Sandra R Knowles; Michael J Rieder; John R Bend; Neil H Shear; Gideon Koren
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

3.  In vitro release of interferon-gamma from peripheral blood lymphocytes in cutaneous adverse drug reactions.

Authors:  Ilan Goldberg; Meital Hanson; Gabriel Chodick; Idit Shirazi; Sarah Brenner
Journal:  Clin Dev Immunol       Date:  2012-06-06

4.  The Dapsone hypersensitivity syndrome revisited: a potentially fatal multisystem disorder with prominent hepatopulmonary manifestations.

Authors:  Semaan G Kosseifi; Bhuvana Guha; Dima N Nassour; David S Chi; Guha Krishnaswamy
Journal:  J Occup Med Toxicol       Date:  2006-06-06       Impact factor: 2.646

5.  Mononucleosis-like drug rash: an interesting case presentation.

Authors:  Reshma T Vishnani; Ram H Malkani; Afsha A Topal; H G Desai
Journal:  J Family Med Prim Care       Date:  2014-01

6.  Dapsone hypersensitivity syndrome: A rare life threatening complication of dapsone therapy.

Authors:  Kolar Vishwanath Vinod; Karyampudi Arun; Tarun Kumar Dutta
Journal:  J Pharmacol Pharmacother       Date:  2013-04

7.  Cervical lymphadenopathy mimicking angioimmunoblastic T-cell lymphoma after dapsone-induced hypersensitivity syndrome.

Authors:  Min Young Rim; Junshik Hong; Inku Yo; Hyeonsu Park; Dong Hae Chung; Jeong Yeal Ahn; Sanghui Park; Jinny Park; Yun Soo Kim; Jae Hoon Lee
Journal:  Korean J Pathol       Date:  2012-12-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.